RAP-219
RAP-219-FOS-901
Phase 2 small_molecule active
Quick answer
RAP-219 for Focal Epilepsy is a Phase 2 program (small_molecule) at Rapport Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rapport Therapeutics
- Indication
- Focal Epilepsy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active